Recent Finacing
Recent Raise
Attovia develops multi-specific, biparatopic nanobody therapeutics using its ATTOBODY platform to target immune-mediated diseases and oncology, advancing anti-IL31 and IL13/IL31 bispecific candidates through preclinical and early clinical stages.
